Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial

JAMA

Volumn 288, Issue 22, 2002, Pages 2827-2835

  Corwin, Howard L ^a   Gettinger, Andrew ^a   Pearl, Ronald G ^b   Fink, Mitchell P ^c   Levy, Mitchell M ^d   Shapiro, Marc J ^e   Corwin, Michael J ^f,h   Colton, Theodore ^g,h  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^h Statistical Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037065340     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.22.2827     Document Type: Article

References (32)

1. Spence RK, Cernaianu AC, Carson J, DelRossi AJ. Transfusion and surgery. Curr Probl Surg. 1993;30:1101-1180.
2. Littenberg B, Corwin H, Gettinger A, Leichter J, AuBuchon J. A practice guideline and decision aid for blood transfusion. Immunohematology. 1995;11:88-92.
3. Corwin HC, Parsonnet KC, Gettinger A. RBC transfusion in the ICU: Is there a reason? Chest. 1995;108:767-771.
4. Groeger JS, Guntupalli KK, Strosberg M, et al. Descriptive analysis of critical care units in the United States: Patient characteristics and intensive care unit utilization. Crit Care Med. 1993;21:279-291.
5. Vincent JL, Baron JF, Gattinoni L, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002; 288:1499-1507.
6. Corwin HL, Abraham E, Fink MP, et al. Anemia and blood transfusion in the critically ill: Current clinical practice in the US - The CRIT Study [abstract]. Crit Care Med. 2001;29(suppl):A2.
7. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine: First of two parts-blood transfusion. N Engl J Med. 1999;340:438-447.
8. Blumberg N, Heal JM. Effects of transfusion on immune function: Cancer recurrence and infection. Arch Pathol Lab Med. 1994;118:371-379.
9. Landers DF, Hill GE, Wong KC, Fox IJ. Blood transfusion-induced immunomodulation. Anesth Analg. 1996;82:187-204.
10. Mickler TA, Longnecker DE. The immunosuppressive aspects of blood transfusion. J Intensive Care Med. 1992;7:176-188.
11. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA. 1993;269:3024-3029.
12. Fitzgerald RD, Martin CM, Dietz GE, Doig GS, Potter RF, Sibbald WJ. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med. 1997;25:726-732.
13. Hebert PC, Wells G, Biajchman MA, et al, for the Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999; 340:409-417.
14. Corwin HL, Krantz S. Anemia in the critically ill: "acute" anemia of chronic disease. Crit Care Med. 2000;28:3098-3099.
15. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care. 2001;16:36-41.
16. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med. 1997;23:159-162.
17. Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. Crit Care Med. 1994;22:821-826.
18. Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol. 1997;273:R1067-R1071.
19. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18:555-559.
20. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized double-blind placebo-controlled trial. Crit Care Med. 1999;27:2346-2350.
21. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alpha in patients undergoing major orthopedic surgery. Am J Orthop. 1996;25:544-552.
22. Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ. A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology. 1999; 91:24-33.
23. Qvist N, Boesby S, Wolff B, Hansen CP. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusions in patients undergoing colorectal surgery-prospective double-blind placebo-controlled study. World J Surg. 1999;23:30-35.
24. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times weekly dosing. J Clin Oncol. 2001;19:2875-2882.
25. Goodnough LT, Johnston MF, Toy PT, for the Transfusion Medicine Academic Award Group. The variability of transfusion practice in coronary artery bypass surgery. JAMA. 1991;265:86-90.
26. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227-234.
27. Casadevall N, Nataf J, Viron B, et al. Pure redcell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
28. Casadevall. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant. 2002;17 (suppl 5):42-47.
29. McRae AD, Weijer C. Lessons from everyday lives: A moral justification for acute care research. Crit Care Med. 2002;30:1146-1151.
30. Burck R. Minimal risk: The debate goes on. Crit Care Med. 2002;30:1180-1181.
31. Myhre BA, McRuer D. Human error: A significant cause of transfusion mortality. Transfusion. 2000; 40:879-885.
32. Spahn DR, Casutt M. Eliminating blood transfusions: New aspects and perspectives. Anesthesiology. 2000;93:242-255.